Abstract:
The apparatus and method for observing infrared emission from excited molecules in samples of interest was investigated. Over the wavelength interval from 1 to 5 mu m, two strong emission bands were observed with a PbSe detector (429) when organic compounds were introduced into a hydrogen/air flame (421). The band at 4.3 mu m (2326 cm ) was due to the asymmetric stretch of carbon dioxide while the band at 2.7 mu m was due to both water and carbon dioxide emission. The carbon dioxide emission at 4.3 mu m was found to be most intense at the tip of the flame (421), and was found to increase with the amount of organic compound introduced into the flame (421). For chromatographic application, an optical filter (428) was used to isolate the 4.3 mu m emission band. The infrared emission detection system finds application in the determination of total inorganic carbon, chloride and available chlorine in aqueous samples. The detector is optimized by use of a dual beam system with background subtraction capabilities thereby eliminating background noise and the fluctuations therein.
Abstract:
A digital frequency domain fluorometer utilizing a computer-controlled digital data acquisition system is used for the study of fluorescence and phosphorescence phenomena in the bio-chemical, biological and bio-physics arts. The computer (808) is used for the direct collection of data, as well as for the filtering and calculation of the phase and modulation values of the sample under study. From these values, fluorescence lifetimes can be determined. The digital data acquisition system (702 and 808) provides for the simultaneous collection and processing of several modulation frequencies. In addition, the digital frequency domain fluorometer can utilize an array detector (72) for detecting the modulated light from the various samples under study. The use of the array detector (72) provides a means for independently collecting data over a large number of pixels. This configuration allows for a time resolved image to be collected at once.
Abstract:
Ceramic electrode materials (14, 16) of the invention include ceramic compositions having significant electrical conductivity at room temperature. The ceramic electrodes (14, 16) are coupled to a dielectric (12) to provide electrical devices such as capacitors(10) and transducers (10). The presently known ceramic compositions having room temperature conductivity are ceramic materials that are superconductors at low temperatures and include compositions of the formula: ZBa2-xAxO9-y, where Z is Y, La or any of the lanthanide series elements; A is Na, K, Rb, Cs or Pb; x is in the range 0.0 to 0.2; and y is about 2.0. Compositions having the formula: Bi2Sr3-xCaxCu2Oy, where x is in the range 0.0 to 2.0 and y is in the range 5.0 to 8.0 may also be used as ceramic electrodes (14, 16). The ceramic electrodes (14, 16) have similar perovskite crystalline structures to the dielectrics (12) forming the electrical devices (10) of the invention.
Abstract:
An assembly comprising a pulley sub assembly (104) and a shift sub assembly (106). The pulley sub assembly includes a plurality of pulleys (116, 120, 122, 124, 126, 130), each pulley includes a plurality of sections (134, 136, 140, 142), and at least one section of each pulley is axially moveable. The shift sub assembly has a disengaged position to maintain the pulleys in normal positions, and an engaged position. With one embodiment (100), when the shift sub-assembly is in the engaged position, it slides a section of a first pulley from the plane thereof, into the plane of a second pulley, and then back into the plane of the first pulley. With an alternate embodiment (400), when the first sub-assembly is in the engaged position, it slides all of the sections of a pulley, one at a time, into the plane of another pulley.
Abstract:
The invention provides a compound of formula (I) wherein R to R , n, X, Y and Z have any of the values defined in the specification; or a pharmaceutically acceptable salt thereof; for use in medical therapy, and in particular, for use in treating an elastase-mediated pathology. The invention also provides novel compounds of formula (I), and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising compounds of formula (I) and their pharmaceutically acceptable salts. The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, to prepare a medicament for treating an elastase-mediated pathology.
Abstract:
A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.
Abstract:
The present invention is directed towards NH2-terminally truncated analogs of three human chemokines: MCP-3, RANTES and MIP-1 alpha having highly potent anti-inflammatory activity and anti-autoimmune activity. The present invention is also directed to inhibiting the biological activities of three native, mammalian chemokines: MCP-3, RANTES and MIP-1 alpha . The present invention is further directed to treating inflammatory diseases and autoimmune disorders such as rheumatoid arthritis, for example. The present invention is also directed to pharmaceutical compositions comprising NH2-terminally truncated chemokine analogs.
Abstract:
The present invention relates to water-soluble, lipophilic contrast-enhancing agents, pharmaceutical compositions thereof and methods for diagnostic analysis, particularly NMR or MRI analysis using these contrast-enhancing agents. The water-soluble, lipophilic contrast-enhancing agents are chelates of a paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with complexing acids which contain at least one short-chain fatty acyl moiety having from about 0 to about 6 carbon atoms in its structure.
Abstract:
The present invention is directed to methods of detection of Alzheimer's disease. In particular, the present invention provides antibodies to the band 3 protein capable of differentiating Alzheimer's disease tissue from normal tissue. In addition, the invention provides a method of detection of Alzheimer's disease comprising determining differential band 3 phosphorylation.
Abstract:
A water wettable permselective membrane for use in hemodialysis, ultrafiltration and microfiltration applications and a device containing the same are provided. The membrane having the above properties comprises a hydrophobic-base polymer, such as a polysulfone or polyethersulfone polymer, and a block copolymer additive wherein one of the blocks of the copolymer additive is a hydrophilic polymer and the other block is a hydrophobic polymer that is analogous in structure to the hydrophobic-base polymer.